PURE Bioscience, Inc., developer of low toxicity bioscience products and antimicrobials, today announced it has taken direct control of the sales of its patented silver dihydrogen citrate (SDC) antimicrobial after the company’s alliance with Richmont Sciences LLC fell short of expectations.

PURE’s current alliance agency agreement with Richmont will default later this month on the grounds that Richmont failed to sell PURE’s products under the brand IV-7; PURE also noted that Richmont failed to pay PURE for delivered products.

“Although we had high expectations and great confidence in Richmont at the time of their engagement, its subsequent anemic sales results are in stark contrast to the very encouraging response our team is receiving with recent marketing efforts of the new PURE brand,” Michael L. Krall, president and CEO of PURE, stated in the press release. “ We are disappointed in Richmont’s lack of commitment, investment, execution and results, as well as its shrinking management team and sales force, and we have been rapidly moving to resume direct control of our sales strategy.”

As part of the new alignment, PURE will market its proprietary PURE™ Hard Surface disinfectant and sanitizer brand through alternative and traditional distribution channels. The company plans to restructure its marketing and distribution strategy, and will sell the product in the consumer, commercial and institutional markets, including the food processing industry.

PURE Hard Surface eliminates dangerous pathogens such as Salmonella, E. coli, Norovirus, Campylobacter, Listeria and Staph (including MRSA). Tom Myers, PURE vice president of sales and marketing, noted how the low-toxicity product appeals to the food industry and how the company will distribute the product from here on out.

“The response to our SDC technology and our branded products is very positive. The food industry in particular is tired of the perceived safety provided by currently available solutions. Bacteria can build resistance to these traditional chemicals, which render them ineffective. SDC not only provides faster and more complete protection, but also unique mechanisms of action that reduce the possibility of forging bacterial resistance,” Myers stated. “We’re building a knowledgeable sales force and establishing qualified distribution channels to present SDC as the new paradigm, and to date have received an enthusiastic response from the market. We have taken the sales strategy for PURE into our own hands and look forward to delivering the SDC technology to decision makers in the U.S. food industry as well as in commercial, consumer and institutional markets.”

For more information visit www.purebio.com